Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Semin Hematol. 2008 Jul;45(3 Suppl 2):S2–S6. doi: 10.1053/j.seminhematol.2008.07.003

Table 2.

Summary of proteasome inhibitors in indolent NHL

Agent Type of inhibitor Clinical status
Bortezomib Reversible Approved for use in MCL
Carfilzomib (PR-171) Irreversible Phase 1 testing
NPI-0052 Irreversible Early phase 1 testing

MCL, mantle cell lymphoma.